201 related articles for article (PubMed ID: 7941303)
1. Bovine NK and LAK susceptibility is independent of class I expression on B lymphoblastoid variants.
Li W; Splitter GA
Vet Immunol Immunopathol; 1994 Jun; 41(3-4):189-200. PubMed ID: 7941303
[TBL] [Abstract][Full Text] [Related]
2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
3. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.
Lobo PI; Chang MY; Mellins E
Immunology; 1996 Aug; 88(4):625-9. PubMed ID: 8881767
[TBL] [Abstract][Full Text] [Related]
5. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
[TBL] [Abstract][Full Text] [Related]
6. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
7. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
Chiang EY; Henson M; Stroynowski I
J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
9. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
11. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
Chang CS; Brossay L; Kronenberg M; Kane KP
J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
[TBL] [Abstract][Full Text] [Related]
12. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
Reiter Z
J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
[TBL] [Abstract][Full Text] [Related]
13. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
14. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
15. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
16. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
[TBL] [Abstract][Full Text] [Related]
17. A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells.
Lobo PI; Patel HC
Immunology; 1994 Oct; 83(2):240-4. PubMed ID: 7835941
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
20. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.
Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D
Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
